Form 4 Filing for Quimi Daphne at Amylyx Pharmaceuticals, Inc.

This filing details a Form 4 submission by Quimi Daphne, who is a director at Amylyx Pharmaceuticals, Inc. The transaction, dated June 4, 2026, involves the acquisition of 24,372 stock options for the company's Common Stock. The options have an exercise price of $14.31 per share and are set to expire on June 3, 2036. A footnote indicates that these options will fully vest on the earlier of June 4, 2027, or the next annual meeting, contingent upon Quimi Daphne's continued service to the company. The filing also notes that Ms. Daphne holds these options directly, with 24,372 shares owned post-transaction. The signature date on the filing is June 8, 2026.